Journal
NEPHRON CLINICAL PRACTICE
Volume 119, Issue 2, Pages C89-C95Publisher
KARGER
DOI: 10.1159/000326682
Keywords
Inflammatory bowel disease; Nephrotoxicity; Tubulointerstitial nephritis; Glomerulonephritis; Aminosalicylates; Cyclosporine; Tumor necrosis factor-alpha inhibitors
Categories
Ask authors/readers for more resources
Conservative management of inflammatory bowel disease (IBD) is based on a combination of drugs, including amino-salicylates (ASAs), steroids, antibiotics, immunosuppressives and biologic agents. Although various side effects have been related to treatment regimens, drug-induced nephrotoxicity is rather uncommon. Furthermore, it is often underestimated since renal function deterioration may be attributed to the underlying disease. The nephrotoxicity of ASAs and cyclosporine A seems well established, but recent data have suggested a possible role of biologic agents such as infliximab and adalimubab in renal impairment. The aim of this review is to summarize the nephrotoxic effects of medical treatment as well as to express possible caveats in the administration of novel agents in IBD. Copyright (C) 2011 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available